Portal de Periódicos da CAPES

The economic costs of NIDDM

1992; Wiley; Volume: 8; Issue: 4 Linguagem: Inglês

10.1002/dmr.5610080406

1099-0895

Thomas J. Songer,

Diabetes Treatment and Management

Diabetes/Metabolism ReviewsVolume 8, Issue 4 p. 389-404 Article The economic costs of NIDDM Thomas J. Songer, Thomas J. Songer Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.Search for more papers by this author Thomas J. Songer, Thomas J. Songer Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.Search for more papers by this author First published: December 1992 https://doi.org/10.1002/dmr.5610080406Citations: 29AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Omran AR: The epidemiologic transition: A theory of the epidemiology of population change. Milbank Mem Fund Q 49: 509–538, 1971. 2 Olshansky SJ, and Ault AB: The fourth stage of the epidemiologic transition: the case of delayed degenerative diseases. The Millbank Quarterly 64: 355–391, 1986. 3 Harris MI, Hadden WC, Knowler WC, and Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes 36: 523–534, 1987. 4 Harris MI: Prevalence of non-insulin-dependent diabetes and impaired glucose tolerance. In Diabetes in America, Diabetes Data Compiled 1984, the National Diabetes Data Group, Eds. U.S. Government Printing Office, Washington, DC, August 1985, NIH Pub. No. 84–1468, pp. VI 1–31. 5 Stern MP, and Haffner SM: Type II diabetes and its complications in Mexican Americans. Diabetes Metab Rev 6: 29–45, 1990. 6 Gardner LI Jr., Stern MP, Haffner SM, Gaskill SP, Hazuda HP, Relethford JH, and Eifler CW: Prevalence of diabetes in Mexican Americans: relationship to percent of gene pool derived from native American sources. Diabetes 33: 86–92, 1984. 7 Knowler WC, Pettitt DJ, Suad MF, and Bennett PH: Diabetes mellitus in the Pima Indians: incidence, risk factors, and pathogenesis. Diabetes Metab Rev 6: 1–27, 1990. 8 Garcia MJ, McNamara PM, Gordon T, and Kannell WB: Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 23: 105–111, 1974. 9 Palumbo PJ, Elveback LR, and Chu-Pin, C: Diabetes mellitus-incidence, prevalence, survivorship, and cause of death. Diabetes 25: 566–573, 1976. 10 Zimmet P, King H, Taylor R, Raper LR, Balkau B, Borger J, Heriot W, and Thoma K: The high prevalence of diabetes mellitus, impaired glucose tolerance and diabetic retinopathy in Nauru—the 1982 survey. Diabetes Res 1: 13–18, 1984. 11 King H, Taylor R, Zimmet P, Pargeter K, Raper LR, Beriki T, and Tekanene J: Non-insulin-dependent diabetes (NIDDM) in a newly independent Pacific nation: the Republic of Kiribati. Diabetes Care 7: 409–415, 1984. 12 Taylor R, Lewis ND, and Levy S: Societies in transition: mortality patterns in Pacific Island populations. Int J Epidemiol 18: 634–646, 1989. 13 Dowse GK, Zimmet PZ, Gareeboo H, Alberti KGMM, Tuomilehto J, Finch CF, Chitson P, and Tulsidas H: Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care 14: 271–282, 1991. 14 Stern MP: Kelly West Lecture: Primary prevention of type II diabetes mellitus. Diabetes Care 14: 399–410, 1991. 15 King H, and Dowd JE: Primary prevention of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33: 3–8, 1990. 16 Zimmet PZ: Primary prevention of diabetes mellitus. Diabetes Care 11: 258–262, 1988. 17 Tuomilehto J: Strategies for primary prevention of NIDDM. Adv Exp Med Biol 246: 403–411, 1988. 18 Lee K, and Mills A: Developing countries, health, and health economics. In The Economics of Health in Developing Countries, K Lee, and A Mills, Eds. Oxford University Press, Oxford, 1983, pp. 1–22. 19 Warner KE, and Hutton RC: Cost-benefit and cost-effectiveness analysis in health care; growth and composition of the literature. Med Care 18: 1069–1084, 1980. 20 Rosenthal G: Of economists and economics, ceteris paribus. Milbank Mem Fund Q Bull 57: 291–296, 1979. 21 DR Cohen, and JB Henderson (Eds): Health, Prevention, and Economics. Oxford University Press, Oxford, 1991. 22 Fein R: Social and economic attitudes shaping American health policy. Milbank Mem Fund Q Bull 57: 297–336, 1979. 23 Mooney GH: Economics, Medicine, and Health Care. Harvester Wheatsheaf, New York, 1986. 24 McGuire A, Henderson J, and Mooney G: The Economics of Health Care, An Introductory Text. Routledge & Kegan Paul, London, 1988. 25 Hodgson TA, and Meiners MR: Cost-of-illness methodology: a guide to curent practices and procedures. Milbank Mem Fund Q 60: 429–460, 1982. 26 Rice DP: Estimating the Cost of Illness, Health Economics Series No. 6, PHS Pub. No. 947–6. US Govt Printing Office, Washington, DC, 1966. 27 Scitovsky AA: Estimating the direct costs of illness. Milbank Mem Fund Q 60: 463–491, 1982. 28 Tolpin HG, and Bentkover JD: Economic cost of illness: decision-making applications and practical considerations. In Advances in Health Economics and Health Services Research, Vol. 4, R Scheffler, and L Rossiter, Eds. JAI Press, Greenwich, CT, 1983, pp. 165–198. 29 Hodgson TA: The state of the art of cost-of-illness estimates. In Advances in Health Economics and Health Services Research, Vol. 4, R Scheffler, and L Rossiter, Eds. JAI Press, Greenwich, CT, 1983, pp. 129–164. 30 Cooper BS, and Rice DP: The economic cost of illness revisited. Soc Sec Bull 39: 21–36, 1976. 31 Rice DP, Hodgson TA, and Kopstein AN: The economic costs of illness: a replication and update. Health Care Financing Rev 7: 61–80, 1985. 32 Songer TJ: The economics of diabetes care. In International Textbook of Diabetes Mellitus, KGMM Alberti, RA DeFronzo, H Keen, and P Zimmet, Eds. John Wiley, London, 1992, pp. 1643–1654. 33 Entmacher PS, Sinnock P, Bostic E, and Harris MI: The economic impact of diabetes. In Diabetes in America, Diabetes Data Compiled 1984, the National Diabetes Data Group, Eds. U.S. Government Printing Office, Washington, DC, August 1985, NIH Pub. No. 84–1468, pp. XXXII 1–13. 34 Fox NA, and Jacobs J: Direct and Indirect Costs of Diabetes in the United States in 1987. American Diabetes Association, Alexandria, VA, 1988. 35 Miller LV: Socio-economic impact of diabetes mellitus. In Diabetes Mellitus and Obesity, BN Brodoff, and SJ Bleicher, Eds. Williams & Wilkins, Baltimore, MD, 1982, pp. 799–803. 36 Huse DM, Oster G, Killen AR, Lacey MJ, and Colditz GA: The economic costs of non-insulin-dependent diabetes mellitus. J Am Med Assoc 262: 2708–2713, 1989. 37 Gerard K, Donaldson C, and Maynard AK: The cost of diabetes. Diabetic Med 6: 164–170, 1989. 38 Laing W, and Williams DRR: Diabetes, A Model for Health Care Management. Office of Health Economics, Paper No. 92, London, October 1989. 39 Jonsson B: Diabetes-the cost of illness and cost of control. An estimate for Sweden 1978. Acta Med Scand 671 (Suppl): 19–27, 1983. 40 Taylor AK: Medical expenditures and insurance coverage for people with diabetes: estimates from the National Medical Care Expenditure Survey. Diabetes Care 10: 87–94, 1987. 41 Drury TF, Montgomery LE, and Cohen BB: Health insurance and health care coverage of adult diabetics. In Diabetics in America, Diabetes Data Compiled 1984, edited by the National Diabetes Data Group, Eds. U.S. Government Printing Office, Washington, DC, August 1985, NIH Pub. No. 84–1468, pp. XXXI 1–14. 42 Songer TJ, LaPorte RE, Dorman JS, Orchard TJ, Becker DJ, and Drash AL: Health, life, and automobile insurance characteristics in adults with IDDM. Diabetes Care 14: 318–324, 1991. 43 Songer TJ, LaPorte RE, Dorman JS, Orchard TJ, Becker DJ, and Drash AL: Employment spectrum of IDDM. Diabetes Care 12: 615–622, 1989. 44 Kantrow AH: Employment experiences of juvenile diabetics: some observations based on a survey. Diabetes 10: 476–481, 1961. 45 Patton A: Employment, the law, and you. Diabetes Forecast 41: 28–36, 1988. 46 Weinstock M, and Haft JI: The effect of illness on employment opportunities. Arch Environ Health 29: 79–83, 1974. 47 Cohen EB, and Mastbaum L: Employment for patients with diabetes. Minn Med 57: 241–244, 1974. 48 LaPorte RE, Songer TJ, Gower IF, Lave LB, and Ekoe JM: Insulin-Using Commercial Motor Vehicle Drivers, Pub. No. FHWA-MC-92–012, U.S. Department of Transportation, Federal Highway Administration, Washington, DC, May 1992. 49 Federal Highway Administration: Code of Federal Regulations (CFR), Title 49, Part 391, Qualifications of Drivers, 1992. 50 Federal Aviation Administration: Code of Federal Regulations (CFR), Title 14, Part 67, Medical Standards and Certification, 1992. 51 Standards of Medical Fitness, Army Reg. 40–501, U.S. Department of the Army, Washington, DC, July 1987. 52 Drummond MF, and Stoddart GL: Principles of economic evaluation of health programs. World Health Stat Q 38: 355–376, 1985. 53 Weisbrod BA: Economic approaches to evaluating a new medical technology, the drug cimetidine. In Economic and Medical Evaluation of Health Care Technologies, AJ Culyer, and B Horisberger, Eds. Springer-Verlag, Berlin, 1983, pp. 188–206. 54 Emery DD, and Schneiderman LJ: Cost-effectiveness analysis in health care. Hastings Center Report, July/August 1989, pp. 8–13. 55 Torrance GW: Measurement of health state utilities for economic appraisal, a review. J Health Economics 5: 1–30, 1986. 56 Thompson MS, Read JL, and Laing M: Feasibility of willingness-to-pay measurement in chronic arthritis. Med Decision Making 4: 195–215, 1984. 57 Lubeck DP, and Yelin EH: A question of value: measuring the impact of chronic disease. The Millbank Quarterly 66: 444–464, 1988. 58 Drummond M, Teeling-Smith G, and Wells N: Economic Evaluation in the Development of Medicines. Office of Health Economics, London, April 1988. 59 Torrance GW: Utility approach to measuring health-related quality of life. J Chron Dis 40: 593–600, 1987. 60 Mills A, and Drummond MF: Economic evaluation of health programmes: glossary of terms. World Health Stat Q 38: 432–434, 1985. 61 Kaplan RM, and Davis WK: Evaluating the costs and benefits of outpatient diabetes education and nutrition counseling. Diabetes Care 9: 81–86, 1986. 62 Udvarhelyi IS, Colditz FA, Rai A, and Epstein AM: Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med 116: 238–244, 1992. 63 Elixhauser A: The cost-effectiveness of preventive care for diabetes mellitus. Diabetes Spectrum 2: 349–353, 1989. 64 Kaplan RM, Hartwell SL, Wilson DK, and Wallace JP: Effects of diet and exercise interventions on control and quality of life in non-insulin-dependent diabetes mellitus. J Gen Intern Med 2: 220–228, 1987. 65 Javitt JC, Canner JK, and Sommer A: Cost-effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology 96: 255–264, 1989. 66 Javitt JC, Canner JK, Frank RG, Steinwachs DM, and Sommer A: Detecting and treating retinopathy in patients with type I diabetes mellitus; a health policy model. Ophthalmology 97: 483–495, 1990. 67 Javitt JC, Aiello LP, Bassi LJ, Chiang YP, and Canner JK: Detecting and treating retinopathy in patients with type I diabetes mellitus; savings associated with improved implementation of current guidelines. Ophthalmology 98: 1565–1574, 1991. 68 Dasbach EJ, Flyback DG, Newcomb PA, Klein R, and Klein BEK: Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 29: 20–39, 1991. 69 Sculpher MJ, Buxton MJ, Ferguson FA, Humphreys JE, Altman JFB, Spiegelhalter DJ, Kirby AJ, Jacob JS, Bacon H, Dudbridge SB, Stead JW, Feest TG, Cheng H, Frankling SL, Courtney P, Talbot JF, Ahmed R, and Dabbs TR: A relative cost-effectiveness analysis of different methods of screening for diabetic retinopathy. Diabetic Med 8: 644–650, 1991. 70 Sculpher MJ, Buxton MJ, Ferguson BA, Spiegel-halter DJ, and Kirby AJ: Screening for diabetic retinopathy: a relative cost-effectiveness analysis of alternative modalities and strategies. Health Economics 1992: 1: 39–51. 71 Lairson DR, Pugh JA, Kapadia AS, Lorimor RJ, Jacobson J and Velez R: Cost-effectiveness of alternative methods for diabetic retinopathy screening. Diabetes Care 15: 1369–1377, 1992. 72 Scheffler RM, Feuchtbaum LB, and Phibbs CS: Prevention: the cost-effectiveness of the California diabetes and pregnancy program. Am J Public Health 82: 168–175, 1992. 73 Lave LB: Injury as externality: an economic perspective of trauma. Accident Anal Prevention 19: 29–37, 1987. 74 Wing RR: Behavioral strategies for weight reduction in obese type II diabetic patients. Diabetes Care 12: 139–144, 1989. 75 Wing RR, Salata R, Marcus M, Nowalk T, and Miaskiewicz S: A very low calorie diet plus behavior modification in the treatment of type II diabetes (Abstract). Diabetes 37 (Suppl 1): 110A, 1988. 76 Wing RR, Epstein LH, Paternostro-Bayles M, Kriska A, Nowalk MP, and Gooding W: Exercise in a behavioral weight control program for obese patients with type II diabetes. Diabetologia 31: 902–909, 1988. 77 Heath GW, Leonard BE, Wilson RH, Kendrick JS, and Powell KE: Community-based exercise intervention: Zuni Diabetes Project. Diabetes Care 10: 579, 1987. 78 American Diabetes Association: Exercise and NIDDM. Diabetes Care 13: 785–789, 1990. 79 Eriksson KF, and Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 34: 891–898, 1991. 80 Drummond M: Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Economics 1: 85–92, 1992. 81 Weinstein MC: The costs of prevention. J Gen Intern Med 5 (Suppl): S89–S92, 1990. 82 Russell LB: Is Prevention Better than Cure? The Brookings Institution, Washington, DC, 1986. 83 Scheffler RM, and Paringer L: A review of the economic evidence on prevention. Med Care 18: 473–484, 1980. Citing Literature Volume8, Issue4December 1992Pages 389-404 ReferencesRelatedInformation